Guangzhou Magpie Pharmaceuticals
China clinical-stage biotech
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
0Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | NMDA receptor / nitric oxide donor (hybrid)Small molecule | Indication not yet linked |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.